The amount of late gadolinium enhancement outperforms current guideline-recommended criteria in the identification of patients with hypertrophic cardiomyopathy at risk of sudden cardiac death
Identifying the patients with hypertrophic cardiomyopathy (HCM) in whom the risk of sudden cardiac death (SCD) justifies the implantation of a cardioverter-defibrillator (ICD) in primary prevention remains cha...
Alcohol septal ablation (ASA) is indicated for symptomatic hypertrophic cardiomyopathy (HC) patients. We sought to analyze the incidence of the 30-day readmission rate, predictors, causes of readmission, and incremental healthcare resource (cost and length of stay) utilization after ASA. Nationwide readmission database from 2010 January to 2015 September was queried to identify 30-day unplanned readmission after ASA for HC by using the International Classification of Disease, 9th Revision, Clinical Modification.
Patients with hypertrophic cardiomyopathy (HC) may require higher energies to terminate ventricular fibrillation (VF); thus, dual coil defibrillation leads are often implanted. However, single coil leads may be preferred in young patients. All patients with HCM implanted with a transvenous ICD from years 2000 to 2014 were included. Of 249 patients, 223 underwent VF testing including 150 with a dual coil lead and 73 a single coil. Patients tested with dual coil compared to single coil had lower successful VF energies (15.7 ± 6.1 joule to 20.2 ± 7.9 joule (p
Hypertrophic cardiomyopathy (HCM) came to prominence in 1958 when Donald Teare described in the British Heart Journal its typical pathological features in 8 patients who died suddenly. The excessive risk of sudden cardiac death (SCD) dominated the early literature and contemporary 21st century studies suggest that the SCD rate is approximately 1% per year . Ventricular arrhythmias are the primary cause of SCD and the development of the implantable cardioverter defibrillator (ICD) in 1980 was a significant milestone.
This study examined the prevalence of WPW and associated outcomes in a cohort of patients with Danon Disease.
Danon Disease (DD) is a rare X-linked disorder due to mutations in the Lysosomal Associated Membrane Protein 2 (LAMP-2) gene. Patients present with cardiac manifestations of hypertrophic cardiomyopathy (HCM) and dilated cardiomyopathy (DCM). The goal of this study is to characterize the longitudinal progression of hypertrophic phenotypes and descriptions of left ventricular strain in DD.
The treatment of end stage hypertrophic cardiomyopathy (HCM) is sometimes complicated because some cases of HCM are not suitable for LVAD. Scarce data exist on outcomes of continuous-flow (CF) LVAD support in these challenging patient cohorts. We evaluated the clinical outcomes of LVAD therapy for patients with HCM.
HCM patients may have increased waitlist (WL) mortality. Given the recent change in prioritizing patients with restrictive and hypertrophic cardiomyopathy requiring mechanical support, we sought to assess whether the policy change would affect the waitlist and post-transplant outcomes in HCM pts.
AbstractA 4-year-old boy with Noonan syndrome accompanied by hypertrophic obstructive cardiomyopathy presented with refractory heart failure owing to severe left ventricular outflow obstruction and mitral regurgitation. He underwent mitral valve replacement and trans-mitral myectomy. The pathology of the resected myocardium was consistent with hypertrophic cardiomyopathy, and the mitral valve leaflets were severely degenerated. Compared with a control patient who is a non-syndromic 4-year-old boy with hypertrophic obstructive cardiomyopathy, mitral pathology was much more severe in Noonan syndrome. Regarding trans-mitral m...
Abstract Background: The terminology "end-stage" has been used to describe hypertrophic cardiomyopathy (HCM) with left ventricular systolic dysfunction (herein referred to as HCM-LVSD), defined when left ventricular ejection fraction (LVEF)
Response by Weissler-Snir and Dorian to Letter Regarding Article, "Hypertrophic Cardiomyopathy-Related Sudden Cardiac Death in Young People in Ontario". Circulation. 2020 Mar 31;141(13):e703-e704 Authors: Weissler-Snir A, Dorian P PMID: 32223681 [PubMed - in process]